Home > Haematology > ASH 2019 > Late-Breaking Abstracts > Adding daratumumab to carfilzomib/dexamethasone prolongs PFS and OS in R/R MM

Adding daratumumab to carfilzomib/dexamethasone prolongs PFS and OS in R/R MM

Expert
Prof. Saad Z. Usmani, UNC-Chapel Hill School of Medicine, USA
Conference
ASH 2019
Trial
Phase 3, CANDOR

In the open-label randomised phase 3 CANDOR trial, the addition of anti-CD38 antibody daratumumab to carfilzomib and dexamethasone reduced the risk of disease progression or death by 37% compared with carfilzomib and dexamethasone alone in patients with relapsed/refractory multiple myeloma (MM).

Prof. Saad Z. Usmani (UNC-Chapel Hill School of Medicine, USA) presented the initial results of the trial, which randomised 466 patients (2:1 ratio) with relapsed/refractory MM previously treated with 1 to 3 prior therapies to either daratumumab + carfilzomib/dexamethasone (n=312) or carfilzomib/dexamethasone alone (n=154) [1]. The primary endpoint of this study was progression-free survival (PFS). Key secondary endpoints were overall response rate, minimal residual disease-negative status, complete response rate at 12 months, overall survival (OS), duration of response, and safety.

The median PFS...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on